Evidence map›Paper›PMID 42539769›Full record

Trial reportDiscover medicine2026

Preliminary safety data from a randomised trial of early versus standard timing of administration of measles-rubella vaccine in Ugandan infants.

Gerald Businge, Natalie G Marchevsky, Ezekiel Mupere, Sarah Kelly, Ilona Kakai, Mary Kyohere, Andrew Edielu, Fortunate Ambangira, Brenda Kakayi, Valerie Tusubira and 6 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Discover medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gerald Businge *Makerere University, Johns Hopkins University Research Collaboration (MU- JHU), Upper Mulago Hill Road, P.O. Box 23491, Kampala, Uganda.
Natalie G Marchevsky *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Ezekiel MupereDepartment of Paediatrics and Child Health School of Medicine College of Health Sciences, Makerere University, Kampala, Uganda.
Sarah KellyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Ilona KakaiOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Mary KyohereCity St. George's, London School of Medicine, London, UK.
Andrew EdieluMakerere University, Johns Hopkins University Research Collaboration (MU- JHU), Upper Mulago Hill Road, P.O. Box 23491, Kampala, Uganda.
Fortunate AmbangiraMakerere University, Johns Hopkins University Research Collaboration (MU- JHU), Upper Mulago Hill Road, P.O. Box 23491, Kampala, Uganda.
Brenda KakayiMakerere University, Johns Hopkins University Research Collaboration (MU- JHU), Upper Mulago Hill Road, P.O. Box 23491, Kampala, Uganda.
Valerie TusubiraMakerere University, Johns Hopkins University Research Collaboration (MU- JHU), Upper Mulago Hill Road, P.O. Box 23491, Kampala, Uganda.
Cleophas KomugishaMakerere University, Johns Hopkins University Research Collaboration (MU- JHU), Upper Mulago Hill Road, P.O. Box 23491, Kampala, Uganda.
Philippa MusokeMakerere University, Johns Hopkins University Research Collaboration (MU- JHU), Upper Mulago Hill Road, P.O. Box 23491, Kampala, Uganda.
Yama F MujadidiOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Merijn W BijlsmaDepartment of General Paediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Kirsty Le Doare *Makerere University, Johns Hopkins University Research Collaboration (MU- JHU), Upper Mulago Hill Road, P.O. Box 23491, Kampala, Uganda.
Merryn Voysey *Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Measles remains a major cause of child morbidity and mortality in low-resource settings. Young infants are particularly at risk of severe disease, with many lacking protective levels of maternal antibodies by six months. Vaccination before nine months in high-burden settings may confer earlier protection; however, concerns exist about its effectiveness at this age. We present early findings on enrolment, safety, and measles infections following the administration of a registered measles-containing vaccine at six months versus nine months (MR1) with a subsequent booster (MR2) at 12 or 18 months of age. Methods: We conducted an open-label randomised controlled non-inferiority trial at four health facilities in Kampala, Uganda. Infants aged 24-28 weeks were randomly assigned to receive MR at six and 12 months (group A), nine and 18 months (group B) or six and 18 months (group C). Infants were electronically randomised in a 1:1:1 ratio using block randomisation of varying sizes, stratified by site, maternal HIV status and baseline haemoglobin level. Caretakers recorded solicited reactions on paper diary cards, with safety-related events evaluated. Findings: 450 infants received MR1 and were enrolled. No differences in local or systemic post-vaccination events between the six and nine months MR1 groups were observed [Local: 21·2% versus 21·9% ( Conclusion: We provide further evidence on the safety of administering a measles-containing vaccine at six months of age. Supplementary Information: The online version contains supplementary material available at 10.1007/s44337-026-00649-x.

Indexed as

Early vaccinationHigh-burden settingsMeaslesReactogenicitySafety

Identifiers

PMID42539769
PMCPMC13424465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.